Zeng Hesong, He Xingwei, Liu Wanjun, Kan Jing, He Liqun, Zhao Jinhe, Chen Cynthia, Zhang Junjie, Chen Shaoliang
Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong Univerisity of Science & Technology, Wuhan 430030, China.
Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Cardiol Discov. 2021 Dec 3;1(1):37-43. doi: 10.1097/CD9.0000000000000014. eCollection 2021 Mar.
Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching (PSM).
This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22, 2019 to March 13, 2020. Patients were divided to Abidol (200 mg, tid, 5-7 days, = 788, 77.3%) and No-Abidol ( = 231, 22.7%) groups. The primary outcome was the mortality during hospitalization.
Among 1019 COVID-19 patients, the age was (60.4 ± 14.5) years. Abidol-treated patients, compared with No-Abidol-treated patients, had a shorter duration from onset of symptoms to admission, less frequent renal dysfunction, lower white blood cell counts (lymphocytes <0.8) and erythrocyte sending rate, lower interleukin-6, higher platelet counts and plasma IgG and oxygen saturation, and less frequent myocardial injury. The mortality during hospitalization before PSM was 17.9% in Abidol group and 34.6% in No-Abidol (hazard ratio (HR) = 2.610, 95% confident interval (CI): 1.980-3.440), all seen in severe and critical patients. After PSM, the in-hospital death was 13.6% in Abidol and 28.6% in No-Abidol group (HR = 2.728, 95% CI: 1.598-4.659).
Abidol-treatment results in less in-hospital death for severe and critical patients with COVID-19. Further randomized study is warranted to confirm the findings from this study.
2019年冠状病毒病（COVID-19）是一场全球公共卫生危机。目前尚无治疗严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的特效抗病毒药物。关于阿比多尔对住院死亡率影响的信息较少。本研究旨在评估倾向评分匹配（PSM）前后阿比多尔对COVID-19患者的治疗效果。
这项回顾性队列研究分析了2019年12月22日至2020年3月13日在中国确诊的1019例COVID-19患者。患者被分为阿比多尔组（200毫克，每日三次，5 - 7天，n = 788，77.3%）和非阿比多尔组（n = 231，22.7%）。主要结局是住院期间的死亡率。
1019例COVID-19患者的年龄为（60.4 ± 14.5）岁。与非阿比多尔治疗的患者相比，阿比多尔治疗的患者从症状出现到入院的时间更短，肾功能不全的发生率更低，白细胞计数（淋巴细胞<0.8）和红细胞沉降率更低，白细胞介素-6水平更低，血小板计数、血浆IgG和血氧饱和度更高，心肌损伤的发生率更低。PSM前，阿比多尔组的住院死亡率为17.9%，非阿比多尔组为34.6%（风险比（HR）= 2.610，95%置信区间（CI）：1.980 - 3.440），均见于重症和危重症患者。PSM后，阿比多尔组的院内死亡率为13.6%，非阿比多尔组为28.6%（HR = 2.728，95% CI：1.598 - 4.659）。
阿比多尔治疗可降低COVID-19重症和危重症患者的院内死亡率。需要进一步的随机研究来证实本研究的结果。
